AliveDx Seeks US FDA’s 510(k) Clearance for MosaiQ AiPlex Multiplex Microarray
Shots:
- The US FDA has received 510(k) Application for MosaiQ AiPlex Multiplex Microarray to improve & accelerate diagnosis of celiac disease
- MosaiQ simplifies serological evaluation with syndromic approach by combining IgA & IgG isotypes to detect IgA deficiency & measure anti-tTG as well as anti-DGP (AU/mL) using just 20 μL of sample in single step, while the CD microassay incl. 5 markers in panel per pts incl. most auto-Abs for detection
- MosaiQ allows a simple workflow with rapid results, detecting ~425 celiac disease markers/hr. with RFID-tagged reagents & loaders accelerating the processes to reduce time, consumables, & errors while improving calibration, quality control, & lab efficiency
Ref: AliveDx | Image: AliveDx
Related News:- Senseonics Seeks the CE Mark Approval for Eversense 365 System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
